WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124580
CAS#: 1771736-69-6
Description: PP-F11N lutetium Lu-177 is a Cholecystokinin 2 Receptor Agonist.
Hodoodo Cat#: H124580
Name: PP-F11N lutetium Lu-177
CAS#: 1771736-69-6
Chemical Formula: C90H120LuN19O35
Exact Mass: 2,201.76
Molecular Weight: 2,203.010
Elemental Analysis: C, 49.07; H, 5.49; Lu, 7.94; N, 12.08; O, 25.42
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: 177Lu-Pp-f11N; 639NVQ0SXF; (177Lu)Pp-f11N; PP-F11N lutetium Lu-177; Lutetium Lu 177 PP-F11N; PP-F11N(177Lu); UNII-639NVQ0SXF
IUPAC/Chemical Name: lutetium(III) 2,2',2''-(10-(31-((1H-indol-3-yl)methyl)-41-amino-40-benzyl-34-butyl-4,7,10,13,16,19-hexakis(2-carboxyethyl)-37-(carboxymethyl)-25-(4-hydroxybenzyl)-22-methyl-2,5,8,11,14,17,20,23,26,29,32,35,38,41-tetradecaoxo-3,6,9,12,15,18,21,24,27,30,33,36,39-tridecaazahentetracontyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
InChi Key: DTEPIUGEQLNRHF-UHFFFAOYSA-K
InChi Code: InChI=1S/C90H123N19O35.Lu/c1-3-4-13-56(83(137)105-66(42-75(125)126)90(144)103-63(79(91)133)39-50-10-6-5-7-11-50)97-89(143)65(41-52-43-92-55-14-9-8-12-54(52)55)96-67(111)44-93-81(135)64(40-51-15-17-53(110)18-16-51)104-80(134)49(2)94-82(136)58(20-26-70(115)116)98-85(139)60(22-28-72(119)120)100-87(141)62(24-30-74(123)124)102-88(142)61(23-29-73(121)122)101-86(140)59(21-27-71(117)118)99-84(138)57(19-25-69(113)114)95-68(112)45-106-31-33-107(46-76(127)128)35-37-109(48-78(131)132)38-36-108(34-32-106)47-77(129)130;/h5-12,14-18,43,49,56-66,92,110H,3-4,13,19-42,44-48H2,1-2H3,(H2,91,133)(H,93,135)(H,94,136)(H,95,112)(H,96,111)(H,97,143)(H,98,139)(H,99,138)(H,100,141)(H,101,140)(H,102,142)(H,103,144)(H,104,134)(H,105,137)(H,113,114)(H,115,116)(H,117,118)(H,119,120)(H,121,122)(H,123,124)(H,125,126)(H,127,128)(H,129,130)(H,131,132);/q;+3/p-3
SMILES Code: CCCCC(C(=O)NC(CC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)CNC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)CN5CCN(CCN(CCN(CC5)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Lu+3]
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 2,203.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli
R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D.
Cholecystokinin 2 Receptor Agonist 177Lu-PP-F11N for Radionuclide
Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. J
Nucl Med. 2020 Apr;61(4):520-526. doi: 10.2967/jnumed.119.233031. Epub 2019 Sep
13. PMID: 31519804; PMCID: PMC7198370.
2: Grzmil M, Qin Y, Schleuniger C, Frank S, Imobersteg S, Blanc A, Spillmann M,
Berger P, Schibli R, Behe M. Pharmacological inhibition of mTORC1 increases
CCKBR-specific tumor uptake of radiolabeled minigastrin analogue
[177Lu]Lu-PP-F11N. Theranostics. 2020 Aug 29;10(24):10861-10873. doi:
10.7150/thno.45440. PMID: 33042258; PMCID: PMC7532663.
3: Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM,
Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Targeting of the
Cholecystokinin-2 Receptor with the Minigastrin Analog 177Lu-DOTA-
PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo
Distribution? J Nucl Med. 2019 Mar;60(3):393-399. doi:
10.2967/jnumed.118.207845. Epub 2018 Jul 12. PMID: 30002107.